Healthcare / Medical DevicesNasdaqCM
$1.06
-0.10 (-8.62%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-23.3M · quality 63.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
32/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$47M
P/E
1.2x
↓EV/EBITDA
N/A
•ROE
192.9%
↑Gross Margin
53.7%
↑Debt/Equity
0.14
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2019–2025 · 6 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-379.8%
FCF / Net income
-0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $12.3M · net income $53.4M · FCF $-46.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | $12.3M | $12.3M | $14.5M | $24.7M | $23.8M | — | — | — |
| Net Income | $53.4M | $53.4M | $-53.9M | $-37.7M | $-32.9M | $-24.8M | $-21.8M | $-11.9M |
| EBITDA | $-15.6M | $-15.6M | $-41.0M | $-31.7M | $-27.3M | $-19.3M | $-9.7M | $-4.6M |
| EPS | 0.87 | 0.87 | -1.86 | -2.07 | -2.38 | -2.38 | -8.88 | — |
| Gross Margin | 53.7% | 53.7% | 46.4% | 44.7% | 48.8% | — | — | — |
| Operating Margin | -149.8% | -149.8% | -133.7% | -83.0% | -125.7% | — | — | — |
| Net Margin | 434.2% | 434.2% | -372.9% | -152.2% | -137.9% | — | — | — |
| Balance Sheet | ||||||||
| Debt/Equity | 0.14 | 0.14 | -0.52 | -0.62 | -4.87 | 0.77 | 0.86 | -0.36 |
| Current Ratio | 2.22 | 2.22 | — | — | — | — | — | — |
| Cash Flow | ||||||||
| Free Cash Flow | $-46.7M | $-46.7M | $-23.3M | $-22.1M | $-22.0M | $-15.8M | $-14.3M | $-7.8M |
| Returns | ||||||||
| ROE | 192.9% | 192.9% | 116.6% | 97.6% | 653.6% | -183.7% | -104.8% | 21.7% |
| Valuation | ||||||||
| P/E | 1.22 | 1.22 | — | — | — | — | — | — |
| P/B | 1.76 | 1.76 | — | — | — | — | — | — |
| Growth & Yield | ||||||||
| Revenue Growth | -15.0% | -15.0% | -41.5% | 3.8% | — | — | — | — |
| EPS Growth | 146.8% | 146.8% | 10.1% | 13.0% | — | 73.2% | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-52.4%
EPS terminal req.
$0.09
Spread vs growth
199.1%
5Y implied EPS CAGR
-33.4%
EPS terminal req.
$0.11
Spread vs growth
180.2%
10Y implied EPS CAGR
-14.4%
EPS terminal req.
$0.18
Spread vs growth
161.2%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-41.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.86 → 0.87
Residual
-41.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.